Latest argenx News & Updates

See the latest news and media coverage for argenx. We track all announcements, press releases, and industry mentions in real time, all in one place.

argenx

Immunology-focused biopharmaceutical company

argenx.com

Headquarters: Boston, United States
Founded year: 2008
Company type: Public company
Number of employees: 2,300–5,000
Industry: Pharmaceuticals

Last updated Today

Latest news about argenx

In short: Argenx acquired Forte Biosciences for $2.2B, achieved FDA label expansion for Vyvgart, and reported record revenue and profitability.

Company announcements

August 27 argenx

argenx completes acquisition of Forte Biosciences to expand pipeline

The $77 per share cash tender offer secures first-in-class anti-CD122 antibody FB102 for treating vitiligo and celiac disease.

August 17 argenx

argenx announces positive topline results from its Phase 3 ALKIVIA trial

The drug demonstrated statistically significant clinical improvements over placebo in immune-mediated necrotizing myopathy and dermatomyositis patients after one year of treatment.

July 27 argenx

argenx acquires Forte Biosciences for $2.2 billion

The deal adds first-in-class anti-CD122 antibody FB102 to its immunology pipeline targeting autoimmune diseases.

July 23 argenx

argenx reports half year 2026 financial results and business update

Second quarter product net sales reached $1.5 billion, a 60% year-over-year increase, and the company expanded VYVGART label to all gMG serotypes.

Media coverage

September 9 European Biotechnology Magazine

Leyden Labs reveals RIGImmune acquisition with Phase 1 data - European Biotechnology Magazine

Belgian-Dutch immunology company argenx has agreed to acquire Forte Biosciences for $2.2 billion (€1.9 billion), gaining FB102, an early-stage antibody that has already produced efficacy...

September 7 Ad hoc news

Argenx stock reacts to fresh analyst opinions after share price drop

The Argenx share fell by around 5 percent on the Nasdaq on September 13, 2026, following a critical analysis, as reported by AAII on September 13, 2026. Current assessments and the...

September 7 ORTEX News

Ortex

Insider activity picked up sharply this week. The biggest single trade came from ARGX. argenx founder and CEO Timothy Van Hauwermeiren filed a $21.1 million...

September 4 Ad hoc news

Argenx stock rises after Q2 2026 revenue surge

The Argenx stock benefits from a strong Q2 2026 with significantly exceeded revenue and profit forecasts, as well as fresh support from analyst ratings and price targets.

Never miss news about argenx

Track argenx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

argenx competitors & trending companies

Browse news for competitors to argenx and other trending companies.